ASH 2022 | MOA of REGN5458 & remaining questions in the field of BCMA-directed therapy for R/R myeloma
Naresh Bumma, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH, describes the mechanism of action (MOA) of REGN5458, a BCMAxCD3 bispecific antibody, and outlines challenges and remaining questions in the field of BCMA-directed therapies, including managing failure to BCMA-directed therapies, and choosing between different BCMA-directed agents. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Janssen: Membership on an entity’s Board of Directors or advisory committees, Other: Ad Board; Sanofi, Genzyme: Other: Ad Board, Speakers Bureau; Amgen: Consultancy, Speakers Bureau.
